Activation of β-catenin by inhibitors of glycogen synthase kinase-3 ameliorates cisplatin-induced cytotoxicity and pro-inflammatory cytokine expression in HEI-OC1 cells

Toxicology

Volumn 320, Issue 1, 2014, Pages 74-82

  Kim, Se Jin ^a   Lim, Jae Young ^a   Lee, Joon No ^a   Choe, Seong Kyu ^a   Kim, Yong Il ^a   Song, Seung Ryel ^a   Cho, Meyoung ^b   So, Hong Seob ^a   Park, Raekil ^a  

^a Wonkwang University   (South Korea)

^b Gunsan Medical Center   (South Korea)

Author keywords

Auditory cells; Cisplatin; Glycogen synthase kinase 3 (GSK 3); Ototoxicity; Pro inflammatory cytokines; Wnt catenin

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; BETA CATENIN; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN P21; PROTEIN P53; PUMA PROTEIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL LINE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; CORTI ORGAN; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE ASSOCIATION; GENE TARGETING; HAIR CELL; HAIR LOSS; HEI OC1 CELL; IN VITRO STUDY; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WNT SIGNALING PATHWAY;

AUDITORY CELLS; CISPLATIN; GLYCOGEN SYNTHASE KINASE-3 (GSK-3); OTOTOXICITY; PRO-INFLAMMATORY CYTOKINES; WNT/Β-CATENIN;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL LINE; CISPLATIN; CYTOKINES; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN-6; MICE; NF-KAPPA B; ORGAN OF CORTI; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899674110     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.01.013     Document Type: Article

References (46)

1. Alam S.A., Ikeda K., Oshima T., Suzuki M., Kawase T., Kikuchi T., Takasaka T. Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear. Res. 2000, 141:28-38.
2. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol. 2003, 23:460-464.
3. Bhat R.V., Shanley J., Correll M.P., Fieles W.E., Keith R.A., Scott C.W., Lee C.M. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:11074-11079.
4. Boulikas T. Poly(ADP-ribose) synthesis in blocked and damaged cells and its relation to carcinogenesis. Anticancer Res. 1992, 12:885-898.
5. Clerici W.J., Hensley K., Dimartino D.L., Butterfield D.A. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear. Res. 1996, 98:116-124.
6. Coghlan M.P., Culbert A.A., Cross D.A., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Roxbee Cox L., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., Holder J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7:793-803.
7. Cohen P., Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 2004, 3:479-487.
8. Crowder R.J., Freeman R.S. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J. Biol. Chem. 2000, 275:34266-34271.
9. Deng J., Miller S.A., Wang H.Y., Xia W., Wen Y., Zhou B.P., Li Y., Lin S.Y., Hung M.C. Beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2002, 2:323-334.
10. El-Deiry W.S. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 2003, 22:7486-7495.
11. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem. 1980, 107:519-527.
12. Essers M.A., de Vries-Smits L.M., Barker N., Polderman P.E., Burgering B.M., Korswagen H.C. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science 2005, 308:1181-1184.
13. Florea A.-M., Busselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 2011, 3:1351-1371.
14. Forde J.E., Dale T.C. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell. Mol. Life Sci. 2007, 64:1930-1944.
15. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.S., Jin O., Woodgett J.R. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406:86-90.
16. Kalinec G.M., Webster P., Lim D.J., Kalinec F. A cochlear cell line as an in vitro system for drug ototoxicity screening. Audiol. Neurootol. 2003, 8:177-189.
17. Kaushal G.P., Kaushal V., Hong X., Shah S.V. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int. 2001, 60:1726-1736.
18. Kim S.J., Park C., Han A.L., Youn M.J., Lee J.H., Kim Y., Kim E.S., Kim H.J., Kim J.K., Lee H.K., Chung S.Y., So H., Park R. Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Hear. Res. 2009, 251:70-82.
19. Klamer G., Song E., Ko K.H., O'brien T.A., Dolnikov A. Using small molecule GSK3beta inhibitors to treat inflammation. Curr. Med. Chem. 2010, 17:2873-2881.
20. Lehwald N., Tao G.Z., Jang K.Y., Sorkin M., Knoefel W.T., Sylvester K.G. Wnt-beta-catenin signaling protects against hepatic ischemia and reperfusion injury in mice. Gastroenterology 2011, 141:707-718. 718 e701-705.
21. Leibbrandt M.E., Wolfgang G.H., Metz A.L., Ozobia A.A., Haskins J.R. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int. 1995, 48:761-770.
22. Li T., Kon N., Jiang L., Tan M., Ludwig T., Zhao Y., Baer R., Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149:1269-1283.
23. Li V.S., Ng S.S., Boersema P.J., Low T.Y., Karthaus W.R., Gerlach J.P., Mohammed S., Heck A.J., Maurice M.M., Mahmoudi T., Clevers H. Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 2012, 149:1245-1256.
24. Liu H., Fergusson M.M., Wu J.J., Rovira I.I., Liu J., Gavrilova O., Lu T., Bao J., Han D., Sack M.N., Finkel T. Wnt signaling regulates hepatic metabolism. Sci. Signal. 2011, 4:ra6.
25. Loberg R.D., Vesely E., Brosius F.C. Enhanced glycogen synthase kinase-3beta activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism. J. Biol. Chem. 2002, 277:41667-44173.
26. Matsushima H., Yonemura K., Ohishi K., Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J. Lab. Clin. Med. 1998, 131:518-526.
27. Medina M., Avila J. Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr. Pharm. Des. 2010, 16:2790-2798.
28. Michalak E.M., Villunger A., Adams J.M., Strasser A. In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008, 15:1019-1029.
29. Niehrs C., Acebron S.P. Wnt signaling: multivesicular bodies hold GSK3 captive. Cell 2010, 143:1044-1046.
30. Ostrow S., Hahn D., Wiernik P.H., Richards R.D. Ophthalmologic toxicity after cis-dichlorodiammineplatinum(II) therapy. Cancer Treat. Rep. 1978, 62:1591-1594.
31. Park H.J., Kim H.J., Bae G.S., Seo S.W., Kim D.Y., Jung W.S., Kim M.S., Song M.Y., Kim E.K., Kwon K.B., Hwang S.Y., Song H.J., Park C.S., Park R.K., Chong M.S., Park S.J. Selective GSK-3beta inhibitors attenuate the cisplatin-induced cytotoxicity of auditory cells. Hear. Res. 2009, 257:53-62.
32. Saito Y., Vandenheede J.R., Cohen P. The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem. J. 1994, 303(Pt. 1):27-31.
33. Sarfstein R., Friedman Y., Attias-Geva Z., Fishman A., Bruchim I., Werner H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PloS One 2013, 8:e61537.
34. Sastry J., Kellie S.J. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr. Hematol. Oncol. 2005, 22:441-445.
35. Shah S.M., Patel C.H., Feng A.S., Kollmar R. Lithium alters the morphology of neurites regenerating from cultured adult spiral ganglion neurons. Hear. Res. 2013, 304:137-144.
36. So H., Kim H., Lee J.H., Park C., Kim Y., Kim E., Kim J.K., Yun K.J., Lee K.M., Lee H.Y., Moon S.K., Lim D.J., Park R. Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J. Assoc. Res. Otolaryngol. 2007, 8:338-355.
37. So H., Kim H., Kim Y., Kim E., Pae H.O., Chung H.T., Kim H.J., Kwon K.B., Lee K.M., Lee H.Y., Moon S.K., Park R. Evidence that cisplatin-induced auditory damage is attenuated by downregulation of pro-inflammatory cytokines via Nrf2/HO-1. J. Assoc. Res. Otolaryngol. 2008, 9:290-306.
38. Song L., De Sarno P., Jope R.S. Central role of glycogen synthase kinase-3beta in endoplasmic reticulum stress-induced caspase-3 activation. J. Biol. Chem. 2002, 277:44701-44708.
39. Song R., Wang X., Mao Y., Li H., Li Z., Xu W., Wang R., Guo T., Jin L., Zhang X., Zhang Y., Zhou N., Hu R., Jia J., Lei Z., Irwin D.M., Niu G., Tan H. Resistin disrupts glycogen synthesis under high insulin and high glucose levels by down-regulating the hepatic levels of GSK3beta. Gene 2013, 529:50-56.
40. Thomas M., Finnegan C.E., Rogers K.M., Purcell J.W., Trimble A., Johnston P.G., Boland M.P. STAT1: a modulator of chemotherapy-induced apoptosis. Cancer Res. 2004, 64:8357-8364.
41. van Ruijven M.W., de Groot J.C., Klis S.F., Smoorenburg G.F. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear. Res. 2005, 205:241-248.
42. Vousden K.H., Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2:594-604.
43. Wang J., Ladrech S., Pujol R., Brabet P., Van De Water T.R., Puel J.L. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res. 2004, 64:9217-9224.
44. Wang S.H., Shih Y.L., Kuo T.C., Ko W.C., Shih C.M. Cadmium toxicity toward autophagy through ROS-activated GSK-3beta in mesangial cells. Toxicol. Sci. 2009, 108:124-131.
45. Watanabe K., Inai S., Jinnouchi K., Bada S., Hess A., Michel O., Yagi T. Nuclear-factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOS II) pathway damages the stria vascularis in cisplatin-treated mice. Anticancer Res. 2002, 22:4081-4085.
46. Watcharasit P., Bijur G.N., Zmijewski J.W., Song L., Zmijewska A., Chen X., Johnson G.V., Jope R.S. Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:7951-7955.